Docetaxel plus carboplatin (DC) may have significant activity in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel-based chemotherapy
Year: 2004
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: M. H. Tay, D. J. George, T. D. Gilligan, S. M. Kelly, L. Appleby, M.-E. Taplin, P. G. Febbo, P. W. Kantoff, W. K. Oh
Institution: Dana-Farber Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2259707804